WHAT’S UP HEALTH
From here you can access all the papers and technical analysis reports produced by LLYC’s Global Health team. A compilation of the latest IDEAS reports, opinion articles and in-depth content we have produced on the sector.
After being diagnosed with cancer, patients experience all kinds of feelings. Public-private partnerships that offer a joint response are key to defeating the disease, but if patients are to regain hope, we also need to employ fact-based communication that gives them the information they need.
Rare diseases are a health issue that affect approximately 6-8% of the global population. According to data from the World Health Organization (WHO), it is estimated that 400 million in seven billion people worldwide suffer from at least one kind of rare disease. Despite the working definition provided the WHO definition, every country does its own statistical analyses, and consequently measures the affected percentage of its population differently.
Threats to public health mean transforming the healthcare sector through technology is a pressing concern.
Technology can help design prevention and wellness models.
Can the biopharmaceutical industry maintain 2020’s favorable position and further boost innovative biologic and biosimilar medicines? The launch of biologic (or biotechnological) medicines unleashed no shortage of controversy
among those unfamiliar with the novel science, but the corresponding controversy surrounding biosimilar medicines was greater still.
The COVID-19 pandemic has shaken the health, social, and economic structure nations all over the world. Against this backdrop, certain industries’ strength and trajectory have been key to not only overcoming this crisis, but also to showcasing a high capacity to respond.